-
Jade Biosciences (JBIO) Misses Q1 EPS by 57c
-
Jade Biosciences (JBIO) PT Raised to $45 at H.C. Wainwright
-
Jade Biosciences (JBIO) PT Raised to $35 at H.C. Wainwright
-
Jade Biosciences (JBIO) PT Raised to $39 at BTIG
-
Jade Biosciences (JBIO) PT Raised to $23 at Guggenheim
-
TD Cowen Reiterates Buy Rating on Jade Biosciences (JBIO): "potential best-in-class"
-
William Blair Starts Jade Biosciences (JBIO) at Outperform
-
BTIG on Jade Biosciences (JBIO): 'We See Sentiment Continuing to Rise for APRIL Inhibitors in IgAN'
-
Jade Biosciences (JBIO) PT Raised to $40 at Stifel: "We like the setup for JADE101"
-
LifeSci Capital Starts Jade Biosciences (JBIO) at Outperform
-
H.C. Wainwright Starts Jade Biosciences (JBIO) at Buy
-
Jade Biosciences outlines 2026 clinical milestones for autoimmune drugs
-
Jade Biosciences (JBIO) files for 3.21M share offering by selling stockholders
-
Clear Street Starts Jade Biosciences (JBIO) at Buy
-
Jade Biosciences (JBIO) files for 16.13M share offering by selling stockholders
-
Jade Biosciences (JBIO) Misses Q3 EPS by 48c
-
Jade Biosciences presents safety data for JADE101 at nephrology conference
-
Jade Biosciences to present JADE101 data at kidney conference
-
BTIG Starts Jade Biosciences (JBIO) at Buy
-
Jade Biosciences unveils JADE201 antibody for autoimmune diseases
-
Jade Biosciences, Inc. (JBIO) Misses Q2 EPS by 55c
-
Jefferies Starts Jade Biosciences (JBIO) at Buy
-
Jade Biosciences (JBIO) Appoints Brad Dahms as Chief Financial Officer
-
Guggenheim Upgrades Jade Biosciences (JBIO) to Buy
-
Stifel Starts Jade Biosciences (JBIO) at Buy
-
TD Cowen Starts Jade Biosciences (JBIO) at Buy

